Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | NOVO B:CPH since announced | Transaction value |
---|---|---|
Cardior Pharmaceuticals GmbH | 4.69% | 1.11bn |
Catalent Inc-Manufacturing Sites Portfolio(3) | 18.86% | -- |
Elan Drug Technologies (DNU>16Sep2011 now 01781A) | 38.26% | 92.42m |
Embark Biotech ApS | 43.67% | 16.22m |
Inversago Pharma Inc | 47.03% | 1.08bn |
Data delayed at least 15 minutes, as of May 24 2024 16:10 BST.